ELIGANT: a Phase 4, interventional, safety study of leuprorelin acetate (ELIGARD(®)) in Asian men with prostate cancer

BACKGROUND: The incidence and mortality rate of men with prostate cancer have been increasing in Asia. ELIGARD(®) is a formulation of leuprorelin acetate whose safety and efficacy have been well-established in Western regions. However, limited safety data are available for Asian populations. METHODS...

Descripción completa

Detalles Bibliográficos
Autores principales: Malek, Rohan, Wu, Sheng-Tang, Serrano, Dennis, Tho, Tran, Umbas, Rainy, Teoh, Jeremy, Lojanapiwat, Bannakji, Ong, Teng Aik, On, Weber Kam, Thai, Sam Minh, Kim, Janet, Pophale, Rupesh, Chiong, Edmund
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8899139/
https://www.ncbi.nlm.nih.gov/pubmed/35280654
http://dx.doi.org/10.21037/tau-21-723

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8899139/
https://www.ncbi.nlm.nih.gov/pubmed/35280654
http://dx.doi.org/10.21037/tau-21-723

Ejemplares similares